3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM). (September 2015) - Grob, J.J.; Amonkar, M.; Karaszewska, B.; Schachter, J.; Dummer, R.; Mackiewicz, A.; Stroiakovski, D.; Drucis, K.; Grange, F.; Chiarion-Sileni, V.; Rutkowski, P.; Lichinitser, M.; et al.